Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Survivin as a Therapeutic Target for the Treatment of Human Cancer

Version 1 : Received: 20 March 2024 / Approved: 20 March 2024 / Online: 21 March 2024 (10:43:55 CET)

How to cite: Wang, Q.; Greene, M.I. Survivin as a Therapeutic Target for the Treatment of Human Cancer. Preprints 2024, 2024031255. https://doi.org/10.20944/preprints202403.1255.v1 Wang, Q.; Greene, M.I. Survivin as a Therapeutic Target for the Treatment of Human Cancer. Preprints 2024, 2024031255. https://doi.org/10.20944/preprints202403.1255.v1

Abstract

Survivin was initially identified as a member of the inhibitor apoptosis (IAP) protein family and has been shown to play a critical role in regulation of both apoptosis and mitosis. Survivin has emerged as an attractive target for cancer therapy because its overexpression has been found in most human cancers and is frequently associated with chemotherapy resistance, recurrence, and poor survival rate in cancer patients. In this review, we discuss our current understanding of how survivin mediates various aspects of malignant transformation and drug resistance, as well as efforts that have been made to develop therapeutics targeting survivin for the treatment of cancer.

Keywords

survivin; cancer; mitosis; apoptosis; Cancer therapy

Subject

Biology and Life Sciences, Biochemistry and Molecular Biology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.